cFLIPL Interrupts IRF3-CBP-DNA Interactions To Inhibit IRF3-Driven Transcription

Area of Science:

• Immunology
• Molecular Biology
• Virology

Background:

• Type I interferons (IFNs) are crucial for antiviral and anticancer immunity.
• Downregulation of type I IFNs is essential for preventing immune system imbalances.
• The role of cellular FLIP long isoform protein (cFLIPL) in type I IFN production is contradictory and mechanistically unclear.

Purpose of the Study:

• To elucidate the mechanism by which cFLIPL regulates type I IFN production.
• To investigate the role of cFLIPL in immune cell development and its implications for cancer therapies.

Main Methods:

• In vitro assays to study protein-protein interactions between cFLIPL and IRF3.
• Analysis of cFLIPL's effect on IRF3 binding to the IFN-β promoter and coactivator proteins.
• Mutational analysis to determine the necessity of cFLIPL nuclear localization for its function.
• Assessment of cFLIPL's impact on IRF3 degradation and phosphorylation.

Main Results:

• cFLIPL directly inhibits IFN regulatory factor 3 (IRF3) activity, a key transcription factor for type I IFN production.
• This inhibition occurs independently of caspase-8 activity and is mediated by cFLIPL binding to IRF3.
• Nuclear localization of cFLIPL is essential for its inhibitory function, preventing IRF3 enhanceosome formation.
• cFLIPL does not induce IRF3 degradation or dephosphorylation, distinguishing it from other IRF3 inhibitors.

Conclusions:

• cFLIPL acts as a novel inhibitor of type I IFN production through a mechanism involving direct interaction with and nuclear sequestration of IRF3.
• This finding provides a new understanding of cFLIPL's role in immune regulation and its potential as a therapeutic target in cancer.